Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02080507 · ClinicalTrials.gov registry record · NA
rTMS in Treatment Resistant Depression
A NA study of Depression, sponsored by Emory University.
- Completed
- Registry status
- NA
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT02080507: Completed NA study of Depression, sponsored by Emory University.
NCT02080507 is a NA study of Depression that has completed, run by Emory University. The registered enrollment target is 12 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02080507, a NA study of Depression, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the safety and efficacy of rTMS as an alternative treatment to ECT. The study will also provide data for a power analysis to support a larger clinical trial if there is evidence of a clinically relevant treatment effect.
Primary Outcome
The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. The MADRS-S instrument has nine questions, with an overall score ranging from 0 to 60 points. A higher score indicates greater depressive symptoms.
Conditions Studied
Interventions
- DEVICE Active Neuronetics rTMS stimulator
- DEVICE Inactive Neuronetics rTMS stimulator
Study Locations (1)
Georgia
- Emory University at Wesley Woods Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2014-03 |
| Est. Completion | 2015-12 |
| Phase | NA |
What the finished NCT02080507 record still lists
NCT02080507 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 786-participant average among 679 other Depression trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 2 interventions - of which Active Neuronetics rTMS stimulator is the first listed.
NCT02080507 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT02080507 about?
NCT02080507 is a clinical study titled "rTMS in Treatment Resistant Depression". The purpose of this study is to determine the safety and efficacy of rTMS as an alternative treatment to ECT. The study will also provide data for a power analysis to support a larger clinical trial if there is evidence of a clinically relevant treatment effect.
What is the current status of trial NCT02080507?
This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2014-03. Estimated completion is 2015-12.
What conditions does trial NCT02080507 study?
This clinical trial studies the following conditions: Depression.
What interventions are being tested in trial NCT02080507?
The interventions under investigation include: Active Neuronetics rTMS stimulator (DEVICE), Inactive Neuronetics rTMS stimulator (DEVICE).
Who is sponsoring clinical trial NCT02080507?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02080507 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02080507's enrollment target sits among peer trials
12 654th of 679 higher than 22 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reaching Out to Distressed Medical Residents, Fellows and Faculty
RECRUITING · NA
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
Cold and Heat Investigation to Lower Levels of Depression
RECRUITING · NA
-
Dosing rTMS for Depression Post-SCI
RECRUITING · NA
-
Exploring Virtual Reality Adventure Training Exergaming
RECRUITING · NA
-
Brief Interventions for Coping with Distress
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia